Novo Holdings

Novo Holdings is a premier life sciences investment firm based in Copenhagen, Denmark, with additional offices in Boston, San Francisco, London, and Singapore. The firm is wholly owned by the Novo Nordisk Foundation and manages an extensive portfolio aimed at generating long-term returns while advancing health and sustainability. Novo Holdings focuses on investments across biotechnology, medical technology, and digital health sectors, supporting companies at various stages, from early development to commercial phases. In 2023, the firm deployed DKK 3.6 billion, including significant investments in 4D Molecular, Alentis Therapeutics, and Lexeo Therapeutics. The firm's strategy emphasizes innovation in patient care and strong financial returns. Notably, Novo Holdings operates with an evergreen fund structure, allowing a long-term perspective on its investments. The firm actively engages with portfolio companies, often taking board positions to leverage its vast network and expertise. The investment team, led by Managing Partner Scott Beardsley, comprises professionals across major life science hubs. Key team members include Amit Kakar, Head of Novo Holdings Asia, and Anna Fan, Senior Partner in the Life Sciences Operating Committee. For startups seeking investment, Novo Holdings values groundbreaking science and robust clinical data, favoring companies with late preclinical or clinical stage compounds in biotech, and commercial stage entities in medtech and digital health